Viridian Therapeutics, Inc./DE: financial reference
Explore Viridian Therapeutics, Inc./DE financial histories from SEC filings, with original units, reporting periods, filing dates and downloadable source data.
Context from the filing
For Viridian Therapeutics, this review covers only the selected 2021–2023 observations in its 2023 annual filing. The filing excludes potential common shares as anti-dilutive in all those loss periods, so basic and diluted loss per share are equal. Full scale-zero share counts follow the statement’s share/per-share exception to the thousands heading. EPS uses net loss rather than comprehensive loss after investment-value changes. This historical review does not establish the accounting treatment of later filings. Read the source filing.
Reported financial histories
Choose a measure to inspect its definition, complete selected history and filing provenance. Each row shows the latest period available for that selected concept and original unit. Separate currencies and reporting intervals remain separate rows. Coverage dates can differ between concepts. A recent capture does not imply recent accounting coverage; these amounts are not prices.
| Measure | Period start | Period end | Value | Unit | Filed |
|---|---|---|---|---|---|
| Total assets | At date | 2025-12-31 | 899,418,000 | USD | 2026-02-26 |
| Total liabilities | At date | 2025-12-31 | 177,251,000 | USD | 2026-02-26 |
| Stockholders equity | At date | 2025-12-31 | 722,167,000 | USD | 2026-02-26 |
| Cash and cash equivalents | At date | 2018-12-31 | 32,606,000 | USD | 2019-03-14 |
| Net income or loss | 2025-01-01 | 2025-12-31 | -342,601,000 | USD | 2026-02-26 |
| Operating cash flow | 2025-01-01 | 2025-12-31 | -276,391,000 | USD | 2026-02-26 |
| Capital expenditure payments | 2025-01-01 | 2025-12-31 | 495,000 | USD | 2026-02-26 |
| Revenue | 2015-01-01 | 2015-12-31 | 5,706,000 | USD | 2016-03-21 |
| Financing cash flow | 2025-01-01 | 2025-12-31 | 426,742,000 | USD | 2026-02-26 |
| Investing cash flow | 2025-01-01 | 2025-12-31 | -37,563,000 | USD | 2026-02-26 |
| Retained earnings or deficit | At date | 2025-12-31 | -1,338,458,000 | USD | 2026-02-26 |
| Basic weighted-average shares | 2023-01-01 | 2023-12-31 | 44,755,475 | shares | 2024-02-27 |
| Diluted weighted-average shares | 2023-01-01 | 2023-12-31 | 44,755,475 | shares | 2024-02-27 |
| Basic earnings per share | 2023-01-01 | 2023-12-31 | -5.31 | USD/shares | 2024-02-27 |
| Diluted earnings per share | 2023-01-01 | 2023-12-31 | -5.31 | USD/shares | 2024-02-27 |
| Net property, plant and equipment | At date | 2025-12-31 | 1,228,000 | USD | 2026-02-26 |
| Share-based compensation expense | 2025-01-01 | 2025-12-31 | 44,303,000 | USD | 2026-02-26 |
| Operating income or loss | 2025-01-01 | 2025-12-31 | -363,395,000 | USD | 2026-02-26 |
| Current assets | At date | 2025-12-31 | 894,233,000 | USD | 2026-02-26 |
| Interest expense | 2022-01-01 | 2022-12-31 | 500,000 | USD | 2023-03-09 |
| Current liabilities | At date | 2025-12-31 | 70,696,000 | USD | 2026-02-26 |
| Current accounts payable | At date | 2025-12-31 | 8,683,000 | USD | 2026-02-26 |
| Net current accounts receivable | At date | 2019-12-31 | 108,000 | USD | 2020-03-13 |
| Operating expenses | 2025-01-01 | 2025-12-31 | 434,244,000 | USD | 2026-02-26 |
| Net inventory | At date | 2016-12-31 | 64,000 | USD | 2017-03-24 |
| Cost of revenue | 2016-01-01 | 2016-12-31 | 2,548,000 | USD | 2017-03-24 |
| Selling, general and administrative expense | 2025-01-01 | 2025-12-31 | 95,315,000 | USD | 2026-02-26 |
| Research and development expense | 2019-01-01 | 2019-12-31 | 34,794,000 | USD | 2020-03-13 |
Inspect the source
- Entity
- Viridian Therapeutics, Inc./DE / CIK 0001590750
- Captured
- 2026-09-20T09:24:00.388Z
- SEC response SHA-256
907b594c863d597442ab1ef3a5d74359a9418f23c7e0bb102180e38d47e78bab
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001590750.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))